ZBIO Zenas BioPharma
Price Chart
Executive Summary
Zenas BioPharma submitted a Biologics License Application (BLA) to the FDA for obexelimab in IgG4-RD, based on positive Phase 3 INDIGO trial results showing a 56% reduction in flare risk (HR 0.44, p=0.0005) and statistical significance on all key secondary endpoints. This is a major regulatory milestone for the company's lead asset, but as a clinical-stage biotech with no approved products, the outcome remains binary pending FDA review.
Actionable Insight
The BLA submission de-risks obexelimab's regulatory path but FDA review (typically 10-12 months) introduces binary risk. Monitor for FDA acceptance and PDUFA date. The upcoming EULAR presentation on June 4 may provide additional data detail. Phase 2 SLE results in Q4 2026 are a secondary catalyst.
Key Facts
- BLA submitted to FDA for obexelimab in IgG4-RD, a chronic fibro-inflammatory disease.
- Phase 3 INDIGO trial met primary endpoint: 56% reduction in IgG4-RD flare risk vs placebo (HR 0.44, p=0.0005).
- All four key secondary endpoints met with high statistical significance.
- Obexelimab was generally well tolerated; data to be presented at EULAR 2026 on June 4.
- Phase 2 SLE trial enrollment completed; topline results expected Q4 2026.
- Zenas is a clinical-stage biotech with no approved products; obexelimab is the lead candidate.
- Market cap ~$1.1B; analyst consensus 86% bullish (12 of 14 analysts rate Buy or Strong Buy).
Financial Impact
BLA submission is a binary catalyst; if approved, obexelimab could address a significant unmet need in IgG4-RD, a disease with no FDA-approved therapies. No financial terms disclosed.
Risk Factors
- FDA may issue a Complete Response Letter (CRL) on safety/efficacy or CMC grounds, which would be highly negative.
- Obexelimab manufacturing relies on WuXi Biologics in China, introducing geopolitical supply chain risk.
- Clinical-stage biotech with no approved products; high cash burn and need for additional financing.
- Competition from other B-cell-targeting therapies in autoimmune diseases.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3302683 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 28, 2026
17d ago
|
Press Release
| $18.56 $18.38 | ▼ −0.97% | ▼ −1.29% | $19.80 (+6.68%) |
|
May 19, 2026
26d ago
|
Press Release
| $17.84 $18.53 | ▲ +3.84% | ▲ +1.59% | $19.80 (+10.99%) |
|
May 13, 2026
4w ago
|
Press Release
| $19.93 $17.84 | ▼ −10.49% | ▼ −9.33% | $19.80 (−0.65%) |
|
May 13, 2026
4w ago
|
8-K
| $19.93 $17.84 | ▼ −10.49% | ▼ −9.33% | $19.80 (−0.65%) |
|
May 13, 2026
4w ago
|
Press Release
| $19.93 $17.84 | ▼ −10.49% | ▼ −9.33% | $19.80 (−0.65%) |
|
Mar 31, 2026
10w ago
|
Insider Cluster
| $19.55 $20.86 | ▲ +6.70% | ▲ +2.76% | $19.80 (+1.28%) |
|
Mar 27, 2026
11w ago
|
Press Release
| $18.21 $22.26 | ▲ +22.24% | ▲ +18.38% | $19.80 (+8.73%) |
|
Mar 26, 2026
11w ago
|
424B5
| $18.21 $22.26 | ▲ +22.24% | ▲ +18.38% | $19.80 (+8.73%) |
|
Mar 26, 2026
11w ago
|
424B5
| $18.21 $22.26 | ▲ +22.24% | ▲ +18.38% | $19.80 (+8.73%) |
|
Mar 16, 2026
12w ago
|
DEFA14A
| $23.23 $20.63 | ▼ −11.19% | ▼ −9.15% | $19.80 (−14.77%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access